‘Snapback’ to Pre-Pandemic Trial Approaches Unlikely, Focus Is on Innovation

As the return to normalcy continues in the post-COVID-19 pandemic world, a new state of the industry report shows that most sponsors and CROs intend to continue using innovative measures adopted during the health crisis and believe such approaches are here to stay. Read More

Despite Pandemic Positives, Crisis Highlights Issues with Growing Use of Service Providers

The COVID-19 crisis showed sites that sponsors and regulatory agencies are capable of moving at unprecedented speed to respond to trial and protocol adaptations. But the pandemic has also revealed some problematic issues, including a growing reliance on technology and service vendors and the siloing of different partners in the trial process. Read More

Biden Administration Lays Out Goals for Potential FDA Regulations

The Biden administration has released its first unified agenda of proposed regulatory actions, a set of goals that include rules to synchronize FDA regulations with requirements of the Common Rule. Read More

NIH Commits to Combating Structural Racism in Biomedical Science

The NIH has come out with a strong commitment to ending structural racism in the biomedical research field, outlining its long-term goals and initial actions in its ongoing push for racial equity. Read More

Firms Name Clinical Research the Most Expensive, Delay-Prone Aspect of Business

A majority of biopharma professionals deemed clinical research to be the most expensive part of their business and the area of drug development with the most bottlenecks, but they’ve taken different approaches to pursuing cost efficiency, a survey found. Read More